PMID- 38143738
OWN - NLM
STAT- MEDLINE
DCOM- 20240102
LR  - 20240404
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Manifestation of subacute cutaneous lupus erythematosus during treatment with 
      anti-PD-1 antibody cemiplimab - a case report.
PG  - 1324231
LID - 10.3389/fimmu.2023.1324231 [doi]
LID - 1324231
AB  - INTRODUCTION: The anti-programmed cell death protein 1 (PD-1) antibody cemiplimab 
      has shown promising results in the treatment of unresectable or metastatic 
      squamous cell carcinoma, however, frequently leads to immune-related adverse 
      events limiting therapy efficacy. Although cutaneous side effects are common, 
      only very few cases of cutaneous lupus erythematosus have been reported under 
      anti-PD-1 immunotherapy. So far, no case of cutaneous lupus has been described 
      under treatment with cemiplimab. CASE REPORT: For the first time, we report the 
      case of a patient with advanced squamous cell carcinoma, who developed clinical 
      and histological findings in sun-exposed skin that were consistent with 
      anti-SS-A/Ro antibody-positive subacute cutaneous lupus erythematosus (SCLE) 
      under treatment with cemiplimab. Additionally, laboratory chemical analyses 
      revealed a severe immune-related hepatitis without clinical symptoms. Both, the 
      SCLE and the hepatitis, resolved after the administration of topical and systemic 
      steroids and the discontinuation of anti-PD-1 therapy. CONCLUSION: Treatment with 
      cemiplimab can be associated with the appearance of cutaneous lupus erythematosus 
      in sun-exposed areas. Application of topical and systemic glucocorticoids can 
      lead to a rapid resolution of the skin eruptions. Moreover, our case illustrates 
      the possibility of simultaneously occurring severe immune-related adverse events. 
      This highlights the importance of additional diagnostics to avoid overlooking 
      additional immune-related adverse events.
CI  - Copyright (c) 2023 Fietz, Frohlich, Mauch, de Vos-Hillebrand, Fetter, Landsberg, 
      Hoffmann and Sirokay.
FAU - Fietz, Simon
AU  - Fietz S
AD  - Center for Skin Diseases Bonn, University Hospital Bonn, Bonn, Germany.
FAU - Frohlich, Anne
AU  - Frohlich A
AD  - Center for Skin Diseases Bonn, University Hospital Bonn, Bonn, Germany.
FAU - Mauch, Cornelia
AU  - Mauch C
AD  - Center for Integrated Oncology, Cologne, Germany.
AD  - Center for Integrated Oncology, Bonn, Germany.
FAU - de Vos-Hillebrand, Luka
AU  - de Vos-Hillebrand L
AD  - Center for Skin Diseases Bonn, University Hospital Bonn, Bonn, Germany.
FAU - Fetter, Tanja
AU  - Fetter T
AD  - Center for Skin Diseases Bonn, University Hospital Bonn, Bonn, Germany.
FAU - Landsberg, Jennifer
AU  - Landsberg J
AD  - Center for Skin Diseases Bonn, University Hospital Bonn, Bonn, Germany.
FAU - Hoffmann, Friederike
AU  - Hoffmann F
AD  - Center for Skin Diseases Bonn, University Hospital Bonn, Bonn, Germany.
FAU - Sirokay, Judith
AU  - Sirokay J
AD  - Center for Skin Diseases Bonn, University Hospital Bonn, Bonn, Germany.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231208
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 6QVL057INT (cemiplimab)
SB  - IM
MH  - Humans
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - *Carcinoma, Squamous Cell/chemically induced/diagnosis/drug therapy
MH  - *Hepatitis
MH  - *Lupus Erythematosus, Cutaneous/chemically induced/diagnosis/drug therapy
PMC - PMC10748382
OTO - NOTNLM
OT  - anti-PD-1 antibody
OT  - case report
OT  - cutaneous lupus erythematosus
OT  - cutaneous squamous cell carcinoma
OT  - immunotherapy
COIS- JS is a consultant/advisory board member and received speaker's honoraria from 
      Novartis, BMS, MSD, and Roche. JL is a consultant/advisory board member and 
      received speaker's honoraria from Novartis, BMS, MSD, and Roche. LV received 
      financial support travel expenses from Pierre Fabre. The remaining authors 
      declare that the research was conducted in the absence of any commercial or 
      financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2023/12/25 06:43
MHDA- 2023/12/26 06:41
PMCR- 2023/01/01
CRDT- 2023/12/25 04:20
PHST- 2023/10/19 00:00 [received]
PHST- 2023/11/22 00:00 [accepted]
PHST- 2023/12/26 06:41 [medline]
PHST- 2023/12/25 06:43 [pubmed]
PHST- 2023/12/25 04:20 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1324231 [doi]
PST - epublish
SO  - Front Immunol. 2023 Dec 8;14:1324231. doi: 10.3389/fimmu.2023.1324231. 
      eCollection 2023.